|
Aug 14
|
SeaStar Medical Holding Corp (ICU) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ...
|
|
Aug 13
|
SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates
|
|
Aug 7
|
SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025
|
|
Aug 6
|
SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)
|
|
Jul 31
|
SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Jul 22
|
SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients
|
|
Jul 16
|
SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry
|
|
Jul 10
|
SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Jul 2
|
SeaStar Medical Announces Positive Nasdaq Listing Determination
|
|
Jun 25
|
Top Midday Gainers
|
|
Jun 25
|
SeaStar Medical Reports Update on Nasdaq Listing Status
|
|
Jun 24
|
SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy
|
|
Jun 20
|
SeaStar Medical Announces Pricing of Up to $8 Million Public Offering
|
|
May 28
|
SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy
|
|
Oct 9
|
SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit
|
|
Oct 8
|
SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities
|
|
Sep 25
|
SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial
|
|
Jul 26
|
Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s
|
|
Jul 23
|
First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device
|
|
Jun 12
|
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
|